Samsung Biologics debuted last week in Seoul with the largest IPO in South Korea in years, according to the Associated Press.
The IPO amount is about half of what the company's competitors, Editas Medicine and Intellia Therapeutics, raised in their own IPOs earlier this year.
In a filing with the US Securities and Exchange Commission, the company said it intends to sell up to $90 million in common stock on the Nasdaq.
The molecular diagnostic company plans to avoid the IPO process but go public in China through a reverse merger with an auto parts maker.
A billionaire entrepreneur is taking his highly valued firm NantHealth public.
The company did not specify the number of shares it will offer or the offering price, but said it intends to trade on the Nasdaq Global Market.
The gene editing firm will concurrently offer 5 million shares to the public and $55 million worth of shares at the same price in a private placement.
BGI is seeking an IPO on a Shenzhen-based stock exchange, but the timing of when this might occur is unclear, FinanceAsia reports.
The CRISPR/Cas9 therapeutics firm could reap billions from the Regeneron collaboration, which includes $75 million up front and a $50 million private placement.
The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.